Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGPAT2 | O15120 | 19/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7258544 | 0.90 | AGPAT2 (1.00) | AGPAT2MAPT | |
| SCHEMBL7262987 | 0.87 | AGPAT2 (1.00) | AGPAT2TP53MAPT | |
| SCHEMBL18460773 | 0.87 | AGPAT2 (0.77) | AGPAT2TP53MAPT | |
| SCHEMBL7258899 | 0.85 | AGPAT2 (0.82) | AGPAT2TP53MAPT | |
| SCHEMBL7263457 | 0.84 | AGPAT2 (1.00) | AGPAT2 | |
| SCHEMBL7258534 | 0.84 | AGPAT2 (0.77) | AGPAT2TP53MAPT | |
| SCHEMBL2242010 | 0.82 | NPC1 (0.77) | AGPAT2TP53MAPT | |
| SCHEMBL4514083 | 0.81 | MAPT (0.73) | AGPAT2TP53MAPT | |
| SCHEMBL7259118 | 0.81 | AGPAT2 (1.00) | AGPAT2TP53MAPT | |
| SCHEMBL4502862 | 0.78 | AGPAT2 (0.85) | AGPAT2TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2002036580-A9 | BENZOXAZOLE LPAAT- BETA INHIBITORS AND USES THEREOF | BONHAM LYNN (US) | 2003-02-13 | — | — | WO | claimed |
| US-20020107269-A1 | Benzoxazole LPAAT-B inhibitors and uses thereof | CELL THERAPEUTICS, INC. | 2002-08-08 | — | — | US | claimed |
| WO-2002036580-A2 | BENZOXAZOLE LPAAT- BETA INHIBITORS AND USES THEREOF | BONHAM LYNN (US) | 2002-05-10 | — | — | WO | claimed |
| WO-2002036580-A9 | BENZOXAZOLE LPAAT- BETA INHIBITORS AND USES THEREOF | BONHAM LYNN (US) | 2003-02-13 | — | — | WO | disclosed |
| US-20020107269-A1 | Benzoxazole LPAAT-B inhibitors and uses thereof | CELL THERAPEUTICS, INC. | 2002-08-08 | — | — | US | disclosed |
| WO-2002036580-A2 | BENZOXAZOLE LPAAT- BETA INHIBITORS AND USES THEREOF | BONHAM LYNN (US) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107269-A1 | Benzoxazole LPAAT-B inhibitors and uses thereof | LPCAT3, LPCAT1, PLAAT2 | AGPAT2 49/4885TP53 3874/4885MAPT 4105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.